{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:49:21Z","timestamp":1766576961553,"version":"3.48.0"},"reference-count":53,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Purpose: Previous data showed an increased risk of developing urinary incontinence in breast cancer patients. However, there is a lack of studies including both pre and postmenopausal women. The aim of this study was to analyze the incidence of subsequent urinary incontinence in breast cancer patients and variables associated with an increased urinary incontinence. Methods: This study utilized IQVIA Disease Analyzer database to examine the five-year cumulative incidence of urinary incontinence among 68,066 women diagnosed with breast cancer in gynecological practices in Germany between January 2005 and December 2021 by using Kaplan\u2013Meier curves, stratified by age group. Multivariable Cox regression models were conducted to assess the association between age, co-diagnoses, and endocrine therapy (tamoxifen, aromatase inhibitors) and incident urinary incontinence. Results: Within five years of the start of follow-up, 5.8% of women were diagnosed with urinary incontinence. Age (HR = 1.36; 95% CI = 1.21\u20131.54 for age 51\u201360; HR = 2.06; 95% CI = 1.84\u20132.31 for age group 61\u201370 and HR = 2.71; 95% CI = 2.42\u20133.04 for age group &gt;70 as compared to age group \u226450), depression (HR = 1.41; 95% CI: 1.25\u20131.59) and menopausal and other perimenopausal disorders (HR = 1.21; 95% CI: 1.10\u20131.27) were associated with an increased urinary incontinence risk. The association was negative and statistically significant for aromatase inhibitor therapy (HR = 0.71; 95% CI: 0.66\u20130.78) as compared to women without endocrine therapy, whereas tamoxifen therapy was not associated with decreased or increased urinary incontinence risk. Conclusions: In conclusion, this study reports an 5.8% incidence of urinary incontinence within five years after breast cancer diagnosis. Age-related differences and co-diagnoses should be taken into account.<\/jats:p>","DOI":"10.3390\/diseases14010003","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:22:14Z","timestamp":1766575334000},"page":"3","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Five-Year Incidence of Urinary Incontinence in 68,066 Breast Cancer Patients Followed in Gynecology Practices in Germany"],"prefix":"10.3390","volume":"14","author":[{"given":"Lara Ilona","family":"Becker","sequence":"first","affiliation":[{"name":"Marburg University, Department of Gynecology and Obstetrics, University Hospital, Baldingerstra\u00dfe, 35043 Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-7227","authenticated-orcid":false,"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[{"name":"Marburg University, Department of Gynecology and Obstetrics, University Hospital, Baldingerstra\u00dfe, 35043 Marburg, Germany"},{"name":"IQVIA, Epidemiology, Unterschweinstiege 2-14, 60549 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kalder","sequence":"additional","affiliation":[{"name":"Marburg University, Department of Gynecology and Obstetrics, University Hospital, Baldingerstra\u00dfe, 35043 Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"ref_1","first-page":"7","article-title":"Cancer Statistics","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global Cancer Incidence and Mortality Rates and Trends\u2014An Update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_3","first-page":"1","article-title":"Tamoxifen or aromatase inhibitors: Which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?","volume":"31","author":"Karaboyun","year":"2023","journal-title":"Support. Care Cancer"},{"key":"ref_4","first-page":"7","article-title":"Cancer statistics","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast Cancer Treatment: A Review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","article-title":"Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer","volume":"126","author":"Hershman","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"102624","DOI":"10.1016\/j.ctrv.2023.102624","article-title":"Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome","volume":"120","author":"Cucciniello","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"26.e1","DOI":"10.1016\/j.ajog.2010.08.035","article-title":"Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer","volume":"204","author":"Baumgart","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3816\/CBC.2009.n.020","article-title":"Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer","volume":"9","author":"Chin","year":"2009","journal-title":"Clin. Breast Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1200\/JCO.2015.64.3866","article-title":"Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study","volume":"34","author":"Ganz","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1055\/s-0040-1718440","article-title":"Urinary Incontinence and Overactive Bladder Symptoms in Women with Breast Cancer Being Treated with Oral Hormone Therapy","volume":"42","author":"Stahlschmidt","year":"2020","journal-title":"Rev. Bras. Ginecol. Obstet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e4107","DOI":"10.1097\/MD.0000000000004107","article-title":"Positive association of female overactive bladder symptoms and estrogen deprivation: A nationwide population-based cohort study in Taiwan","volume":"95","author":"Cheng","year":"2016","journal-title":"Medicine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/1754045313511398","article-title":"The effect of hormones on the lower urinary tract","volume":"19","author":"Robinson","year":"2013","journal-title":"Menopause Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1258\/mi.2010.010020","article-title":"The postmenopausal bladder","volume":"16","author":"Hillard","year":"2010","journal-title":"Menopause Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/1758834016687260","article-title":"A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy","volume":"9","author":"Sousa","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/1471-2407-13-377","article-title":"Urinary incontinence and health-related quality of life among older Americans with and without cancer: A cross-sectional study","volume":"13","author":"White","year":"2013","journal-title":"BMC Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jpsychires.2021.07.018","article-title":"Factors associated with the diagnosis of depression in women followed in gynecological practices in Germany","volume":"141","author":"Drewes","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s11764-014-0360-8","article-title":"Coexistence of urinary incontinence and major depressive disorder with health-related quality of life in older Americans with and without cancer","volume":"8","author":"White","year":"2014","journal-title":"J. Cancer Surviv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102236","DOI":"10.1016\/j.esmoop.2024.102236","article-title":"Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes","volume":"9","author":"Franzoi","year":"2024","journal-title":"ESMO Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/oncolo\/oyae146","article-title":"Quality of life in women with early-stage and metastatic hormone receptor-positive, HER2-negative breast cancer receiving endocrine therapy","volume":"29","author":"Farooq","year":"2024","journal-title":"Oncologist"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1007\/s00432-022-04376-5","article-title":"Persistence with tamoxifen and aromatase inhibitors in Germany: A retrospective cohort study with 284,383 patients","volume":"149","author":"Gremke","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1016\/S1470-2045(20)30666-5","article-title":"Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer","volume":"22","author":"Franzoi","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"712","DOI":"10.6004\/jnccn.2020.7535","article-title":"Serial Assessment of Urinary Incontinence in Breast Cancer Survivors Undergoing (Neo)Adjuvant Therapy","volume":"18","author":"Chung","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdz298","article-title":"Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: A prospective patient-reported outcomes analysis","volume":"30","author":"Ferreira","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_26","first-page":"3799","article-title":"Adherence and quality of life in women with breast cancer being treated with oral hormone therapy","volume":"27","author":"Stahlschmidt","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_27","first-page":"3115","article-title":"Women\u2019s experiences of hormonal therapy for breast cancer: Exploring influences on medication-taking behaviour","volume":"23","author":"Cahir","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.5414\/CP203320","article-title":"Basic characteristics and representativeness of the German Disease Analyzer database","volume":"56","author":"Rathmann","year":"2018","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000513234","article-title":"Multiple Sclerosis and Incidence of Urinary and Fecal Incontinence in Almost 9000 Patients Followed Up for up to 10 Years in Germany","volume":"55","author":"Jacob","year":"2021","journal-title":"Neuroepidemiology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00384-019-03450-8","article-title":"Fecal and urinary incontinence are major problems associated with rectal cancer","volume":"35","author":"Schiffmann","year":"2020","journal-title":"Int. J. Color. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13697137.2018.1543263","article-title":"The prevalence of urinary incontinence","volume":"22","author":"Milsom","year":"2019","journal-title":"Climacteric"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100455","DOI":"10.1016\/j.bjpt.2022.100455","article-title":"Occurrence and impact of pelvic floor dysfunction in women with and without breast cancer: A cross-sectional study","volume":"26","author":"Colombage","year":"2022","journal-title":"Braz. J. Phys. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/nau.24531","article-title":"Prevalence and impact of bladder and bowel disorders in women with breast cancer: A systematic review with meta-analysis","volume":"40","author":"Colombage","year":"2021","journal-title":"Neurourol. Urodyn."},{"key":"ref_34","first-page":"e5417","article-title":"Is Tamoxifen Use a Factor Affecting Continence in Breast Cancer Patients?","volume":"11","author":"Imamoglu","year":"2019","journal-title":"Cureus"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Est\u00e9vez, L., Gonz\u00e1lez-Rodr\u00edguez, M., Calvo, I., Orta, A., Gi\u00f3n, M., Moreno-Bueno, G., P\u00e9rez-Garc\u00eda, J., and Cort\u00e9s, J. (2025). Obesity, overweight and breast cancer: New clinical data and implications for practice. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1579876"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ajog.2005.07.051","article-title":"Risk factors for urinary incontinence among middle-aged women","volume":"194","author":"Danforth","year":"2006","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00001813-200409000-00003","article-title":"Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients","volume":"15","author":"Morales","year":"2004","journal-title":"Anti-Cancer Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/nau.22235","article-title":"Predictors of care seeking in women with urinary incontinence","volume":"31","author":"Minassian","year":"2012","journal-title":"Neurourol. Urodyn."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/pon.1033","article-title":"Psychometric properties of a tool for measuring hormone-related symptoms in breast cancer survivors","volume":"15","author":"Alfano","year":"2006","journal-title":"Psycho-Oncology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/annonc\/mdl299","article-title":"Menopausal-type symptoms in young breast cancer survivors","volume":"17","author":"Leining","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/jnci\/djk154","article-title":"Tamoxifen for the prevention of breast cancer: Late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy","volume":"99","author":"Veronesi","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer","volume":"379","author":"Francis","year":"2018","journal-title":"New Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1089\/whr.2021.0147","article-title":"Challenges of Managing Lower Urinary Tract Symptoms in Women with Tamoxifen Use","volume":"3","author":"Fan","year":"2022","journal-title":"Women\u2019s Health Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.maturitas.2008.02.010","article-title":"Morphometric analysis of the urethra of castrated female rats treated with tamoxifen","volume":"59","author":"Campos","year":"2008","journal-title":"Maturitas"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e6785","DOI":"10.1097\/MD.0000000000006785","article-title":"Effects of tamoxifen on urinary incontinence: Case report and review of literature","volume":"96","author":"Hasanov","year":"2017","journal-title":"Medicine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00192-004-1212-2","article-title":"Effects of tamoxifen on Doppler velocimetry parameters of periurethral vessels in postmenopausal women","volume":"16","author":"Faria","year":"2005","journal-title":"Int. Urogynecology J."},{"key":"ref_47","first-page":"493","article-title":"Collagen type III biosynthesis by cultured pubocervical fascia fibroblasts surrounding mono and multifilament polypropylene mesh after estrogens and tamoxifen treatment","volume":"81","author":"Tomaszewski","year":"2010","journal-title":"Ginekol Pol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1055\/s-2004-821314","article-title":"In vivo properties of the urinary bladder wall and their modulation by estradiol and raloxifene in a rat model","volume":"112","author":"Schultens","year":"2004","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.tips.2006.07.002","article-title":"Rho kinase: A target for treating urinary bladder dysfunction?","volume":"27","author":"Peters","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_50","first-page":"1325","article-title":"Endocrine therapy and urogenital outcomes among women with a breast cancer diagnosis","volume":"27","author":"Landi","year":"2016","journal-title":"Cancer Causes Control."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/pds.705","article-title":"Selective serotonin reuptake inhibitor-induced urinary incontinence","volume":"11","author":"Movig","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_52","first-page":"8139","article-title":"Experiences of pelvic floor dysfunction and treatment in women with breast cancer: A qualitative study","volume":"30","author":"Colombage","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/GME.0000000000000926","article-title":"Missing documentation in breast cancer survivors: Genitourinary syndrome of menopause","volume":"24","author":"Cook","year":"2017","journal-title":"Menopause"}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/1\/3\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:44:29Z","timestamp":1766576669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/1\/3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["diseases14010003"],"URL":"https:\/\/doi.org\/10.3390\/diseases14010003","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]}}}